As of May 27
| -0.0032 / -0.38%|
The 1 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 2.40, with a high estimate of 2.40 and a low estimate of 2.40. The median estimate represents a +186.77% increase from the last price of 0.84.
The current consensus among 1 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.